口服,囊化,冷的便微生物群移植用于复发性Clostridium difficile感染
Ilan Youngster1, George H Russell2, Christina Pindar3
1Division of Infectious Diseases, Massachusetts General Hospital, Boston2Harvard Medical School, Boston, Massachusetts3Division of Infectious Diseases, Boston Children's Hospital, Boston, Massachusetts.
JAMA
|October 17, 2014
概括
便微生物种移植 (FMT) 囊在90%的患有复发性C. difficile感染的患者中安全地解决了腹. 这项研究显示了FMT作为可行的治疗选择的有希望的结果.
科学领域:
- 胃肠病学 胃肠病学
- 微生物组研究的研究.
- 传染病 传染病 传染病
背景情况:
- 复发性困难菌感染 (CDI) 带来了治疗挑战.
- 便微生物群移植 (FMT) 显示出有效性,但面临实际和安全障碍.
- 基于囊的FMT提供了一个潜在的更容易获得的药物管理途径.
研究的目的:
- 评估来自非相关捐赠者的冷,封装FMT的安全性和有效性.
- 为了确定在患有复发性CDI的患者中腹解消的速度.
- 评估患者幸福感和排便频率的改善情况.
主要方法:
- 开放式,单一组可行性研究.
- 20名患有复发性CDI的患者在两天内接受了15个FMT囊.
- 通过不良事件评估安全性;通过8周腹解决的疗效.
主要成果:
- 没有观察到与FMT相关的严重不良事件.
- 在一次FMT疗程后,腹在70%的患者中消失了,在重新治疗后,整体90%的解决方案.
- 肠道排便频率和自我报告的健康评分有显著的改善.
结论:
- 冷,封装的FMT是复发性CDI的安全和有效选择.
- 这种方法表明腹解决率高,生活质量改善.
- 需要进行更大规模的研究来确认长期的安全性和有效性.
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
990
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
990
Drugs for Treatment of Constipation-Predominant IBS
1.4K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.4K
Microbiota of the Large Intestine
89
The large intestine hosts the most densely populated microbial ecosystem in the human body. This complex community primarily consists of anaerobic bacteria, with Bacillota (formerly Firmicutes) and Bacteroidota (formerly Bacteroidetes) as the predominant groups. The distribution of these microbes varies along different sections of the large intestine, influenced by local environmental factors such as oxygen availability and nutrient composition.The cecum, located at the beginning of the large...
89
Drugs for Treatment of Ulcerative Colitis in IBD
689
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
689
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
734
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
734


